Cosmo Pharmaceuticals N.V.

Cosmo Pharmaceuticals N.V. is a pharmaceutical company specializing in the development and commercialization of innovative products for gastroenterology, dermatology, and health technology worldwide. Its portfolio includes GI Genius, an AI-powered computer-assisted system for real-time detection of colorectal lesions during colonoscopies; Winlevi, a topical prescription treatment for acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet for inducing remission in mild to moderate ulcerative colitis; and Uceris/Cortiment, an oral budesonide formulation targeting the colon. Additional offerings encompass Eleview for safer gastrointestinal lesion excision, Lumeblue for enhanced lesion visualization, Aemcolo/Relafalk for travelers' diarrhea, and Byfavo, an intravenous sedative. The company advances a robust pipeline, including Breezula in Phase III trials as a scalp androgen receptor inhibitor for hair loss, Rifamycin enema in Phase II for ulcerative colitis, and early-stage candidates like Colesevelam for bile acid diarrhea and Cortexolone derivatives for solid tumors. Headquartered in Dublin, Ireland, and founded in 1997, Cosmo Pharmaceuticals N.V. partners globally with entities like Medtronic and Bausch Health to distribute its specialized therapies, playing a key role in addressing unmet needs in digestive health, skin conditions, and endoscopic diagnostics.